Azarest 300 mg (Azacitidine): Uses, Dosage, Side Effects & Safety
Azarest 300 mg (Azacitidine): Uses, Dosage, Side Effects & Safety
What Is Azarest 300 mg?
Azarest 300 mg contains azacitidine, a nucleoside metabolic inhibitor used as an anticancer medicine. The product information supplied for this page identifies the product as Azarest 300 mg, with Azacitidine as the generic name and a pack size of 14 tablets.
Oral azacitidine 300 mg has a specific therapeutic role in the continued treatment of certain adults with acute myeloid leukemia (AML). Current FDA prescribing information for oral azacitidine states that it is indicated for adults with AML who have achieved a first complete remission, or complete remission with incomplete blood count recovery, after intensive induction chemotherapy and who are unable to complete intensive curative therapy.
Azacitidine is available in different formulations and treatment regimens. An important safety point is that oral azacitidine 300 mg should not be substituted for injectable azacitidine, because their indications and dosing schedules are different.
Azacitidine Uses
Oral azacitidine is primarily used as continued treatment for appropriately selected adults with AML following intensive induction chemotherapy.
Acute Myeloid Leukemia
AML is a cancer of blood-forming cells in which abnormal myeloid cells accumulate in the bone marrow and blood.
For the current U.S. oral azacitidine indication, patients have already achieved a first complete remission or complete remission with incomplete blood-count recovery after intensive induction chemotherapy but are unable to complete intensive curative treatment.
Patient-Friendly Explanation
Azacitidine tablets may be used after initial intensive AML treatment to continue therapy and help maintain disease control in patients who meet the appropriate treatment criteria.
Medical Explanation
Azacitidine is a cytidine nucleoside analogue that can affect DNA methylation and cellular processes involved in abnormal blood-cell development. Its pharmacological effects contribute to changes in gene expression and cellular differentiation.
How Does Azacitidine Work?
Azacitidine belongs to the class of nucleoside metabolic inhibitors.
After entering cells, azacitidine undergoes intracellular metabolic conversion to active nucleotide forms. These metabolites can become incorporated into RNA and DNA.
One important biological effect involves inhibition of DNA methyltransferase activity.
DNA methylation is an epigenetic process that can influence whether specific genes are active or suppressed. Abnormal DNA methylation patterns are associated with the biology of several hematologic malignancies.
Azacitidine can interfere with abnormal methylation processes and may promote changes in gene expression.
A simplified pathway is:
Azacitidine → intracellular activation → incorporation into cellular nucleic acids → altered methylation/signalling → changes in abnormal cell behaviour
At higher cellular exposures, azacitidine can also interfere with nucleic-acid synthesis and contribute to cytotoxic effects.
The overall therapeutic objective is to interfere with biological processes that support malignant blood-cell survival and proliferation.
The exact clinical response depends on disease characteristics, previous therapy, patient factors and the specific treatment regimen.
Key Indication
Acute Myeloid Leukemia (AML)
Oral azacitidine is indicated in the U.S. for continued treatment of adult patients with AML who have achieved first complete remission or complete remission with incomplete blood count recovery following intensive induction chemotherapy and are not able to complete intensive curative therapy.
This is an important distinction: oral azacitidine is not simply interchangeable with injectable azacitidine. The FDA specifically warns against substitution because the indications and dosing regimens differ.
Azarest 300 mg Dosage & Administration
For the FDA-approved oral azacitidine product, the recommended dosage is:
300 mg orally once daily on Days 1 through 14 of each 28-day cycle.
An antiemetic is recommended before each dose for at least the first two treatment cycles.
Important Instructions
- Take the medicine exactly as prescribed.
- Follow the treatment cycle specified by the oncologist.
- Do not substitute oral azacitidine for injectable azacitidine.
- Do not change the dose without medical supervision.
- An anti-nausea medicine may be prescribed before administration.
- Regular blood-count monitoring is important during treatment.
Missed Dose
Patients should follow the specific missed-dose instructions supplied with their prescription and contact their healthcare professional if they are uncertain.
Do not take an extra dose to compensate unless specifically instructed.
Monitoring
The current FDA label recommends complete blood-count monitoring every other week during the first two cycles and before each subsequent cycle, with additional monitoring after dose reductions when indicated.
Azacitidine Side Effects
Azacitidine can cause adverse effects, and the severity varies between individuals.
Common Side Effects
Reported adverse reactions include:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Fatigue or weakness
- Decreased appetite
- Abdominal pain
- Upper respiratory tract infection
- Pneumonia
- Joint pain
- Dizziness
- Febrile neutropenia
These are among the adverse reactions listed in the current FDA prescribing information for oral azacitidine.
Less Common Side Effects
Other clinically relevant effects may include:
- Low platelet count
- Low white blood-cell count
- Low neutrophil count
- Anaemia
- Skin infections
- Pain in the extremities
- Changes in kidney function
- Electrolyte abnormalities
Serious Side Effects
Important safety concerns include:
- Severe myelosuppression
- Febrile neutropenia
- Serious infections
- Pneumonia
- Severe gastrointestinal toxicity
- Embryo-fetal toxicity
The FDA specifically identifies myelosuppression as an important warning associated with oral azacitidine.
When to Seek Medical Attention
Urgent medical assessment may be necessary for:
- Fever or chills
- Difficulty breathing
- Severe or persistent vomiting
- Severe diarrhea
- Unusual bleeding
- Black or bloody stools
- Extreme weakness
- Signs of infection
- Severe abdominal symptoms
Drug Interactions
Patients should tell their doctor about every prescription medicine, over-the-counter medicine, vitamin, herbal product and supplement they use.
Medicines Requiring Monitoring
The oncology team may need to review:
- Medicines affecting bone marrow function
- Anticoagulants
- Antiplatelet medicines
- Medicines affecting kidney function
- Medicines that may worsen gastrointestinal toxicity
- Other anticancer medicines
Food Considerations
Patients should follow the administration instructions provided with their specific oral azacitidine product.
Do not alter the administration schedule without medical advice.
Supplement Considerations
Discuss the use of:
- Herbal products
- Traditional medicines
- High-dose vitamins
- Mineral supplements
- Unregulated cancer supplements
with the treating healthcare professional before using them during therapy.
Warnings and Precautions
Myelosuppression
Azacitidine can suppress bone-marrow function, leading to reduced blood-cell counts.
This can increase the risk of:
- Infection
- Bleeding
- Anaemia
- Fever associated with low neutrophil counts
Regular blood testing is therefore an important part of treatment monitoring.
Infection Risk
Low white-cell and neutrophil counts can make patients more vulnerable to infections.
Fever, chills, persistent cough or other signs of infection should be reported promptly.
Bleeding Risk
Low platelet counts can increase bleeding risk.
Patients should report:
- Unusual bruising
- Nosebleeds
- Bleeding gums
- Blood in urine
- Blood in stool
- Prolonged bleeding
Kidney Considerations
Kidney function may require monitoring during treatment, particularly in patients with existing renal problems or other risk factors.
Pregnancy Considerations
Azacitidine can cause fetal harm. Appropriate pregnancy-prevention measures should be discussed with the treating healthcare professional.
Pregnancy and Breastfeeding
Azacitidine may cause embryo-fetal harm.
Patients who are pregnant, planning pregnancy or capable of becoming pregnant should discuss treatment with their healthcare professional before starting therapy.
The current FDA prescribing information advises patients about fetal risk and recommends effective contraception.
Breastfeeding is not recommended during treatment with oral azacitidine according to the current FDA labeling.
Special Populations
Elderly Patients
AML commonly affects older adults, and treatment decisions should take into account:
- Overall functional status
- Other medical conditions
- Kidney and liver function
- Previous cancer treatment
- Infection risk
- Blood-count abnormalities
Pediatric Patients
The appropriate use of oral azacitidine in children depends on the specific indication and regulatory approval. Pediatric patients should only receive treatment under specialist oncology supervision.
Renal Impairment
Patients with reduced kidney function should inform their physician before treatment.
Renal function may require closer monitoring during therapy.
Hepatic Impairment
Patients with liver disease should discuss their condition with the treating physician before starting treatment.
The oncology team can determine appropriate monitoring based on clinical circumstances.
Storage
Store Azarest according to the storage instructions stated on the product packaging.
General precautions include:
- Keep tablets in the original packaging.
- Protect the medicine from excessive moisture and heat.
- Keep away from children.
- Do not use damaged tablets.
- Follow the manufacturer's labelled storage conditions.
- Do not transfer tablets into another container unless specifically instructed by a pharmacist.
Frequently Asked Questions
1. What is Azarest 300 mg used for?
Azarest 300 mg contains azacitidine. Oral azacitidine 300 mg is used in specific adult patients with AML who meet the approved treatment criteria following intensive induction chemotherapy.
2. What is Azacitidine?
Azacitidine is a nucleoside metabolic inhibitor used in the treatment of certain blood cancers.
3. Is Azarest 300 mg chemotherapy?
Azacitidine is an anticancer medicine with cytotoxic and epigenetic effects. It is commonly classified as an antineoplastic agent rather than conventional chemotherapy in the traditional sense.
4. How does Azacitidine work?
Azacitidine is metabolically activated inside cells and can affect DNA methylation and nucleic-acid synthesis, altering processes involved in malignant-cell survival and growth.
5. What is the usual oral azacitidine dose?
The FDA-approved oral regimen is 300 mg once daily on Days 1 through 14 of a 28-day cycle.
6. Can oral Azacitidine replace injectable Azacitidine?
No. The FDA specifically warns that oral azacitidine should not be substituted for intravenous or subcutaneous azacitidine because their indications and dosing schedules differ.
7. What are common Azacitidine side effects?
Common adverse reactions include nausea, vomiting, diarrhea, fatigue, constipation, decreased appetite and other gastrointestinal or blood-related effects.
8. Can Azacitidine lower blood counts?
Yes. Myelosuppression is an important safety concern and can result in low white cells, neutrophils, platelets and haemoglobin.
9. Does Azacitidine require blood tests?
Yes. Regular complete blood counts are an important component of monitoring during treatment.
10. Can Azacitidine cause infection?
Yes. Reduced blood-cell counts can increase infection risk, and serious infections have been reported.
11. Can Azacitidine cause nausea?
Yes. Nausea and vomiting are among the commonly reported adverse reactions. An antiemetic is recommended before each dose for at least the first two cycles of oral azacitidine treatment.
12. Can Azacitidine be used during pregnancy?
Azacitidine can cause fetal harm and should only be used during pregnancy when specifically determined appropriate by the treating medical team.
13. Can I breastfeed while taking Azacitidine?
The current FDA prescribing information advises against breastfeeding during oral azacitidine treatment.
14. Is Azacitidine used for AML?
Yes. Oral azacitidine is approved for continued treatment of certain adults with AML following intensive induction chemotherapy.
15. Is Azarest 300 mg the same as injectable azacitidine?
The active ingredient is azacitidine, but oral and injectable formulations have different indications and dosing regimens and should not be treated as interchangeable.
Global Medicine Information & Support by RootAid Pharma
Global Medicine Information & Support by RootAid Pharma
RootAid Pharma provides medicine-information and specialty pharmaceutical support for individuals and organizations seeking information about prescription and high-value medicines.
Our educational resources can help visitors understand:
- Oncology medicines
- Hematology treatments
- AML medicines
- Prescription medicine information
- Dosage and administration guidance
- Safety and precaution information
- Drug interaction considerations
- International medicine information
- Specialty medicine support
For medicines such as azacitidine, treatment should be managed by a qualified hematologist or oncologist.
RootAid Pharma provides medicine-related information and supply assistance where legally and operationally applicable. Product availability, prescription requirements, import regulations and local medicine laws can differ between countries.
RootAid Pharma does not replace a physician, oncologist or pharmacist and does not claim to manufacture Azarest or azacitidine.
Medical Disclaimer
This article is provided for general educational and informational purposes only. It does not replace medical diagnosis, individualized treatment planning, official prescribing information or advice from a qualified physician, hematologist, oncologist or pharmacist.
Azacitidine is a prescription anticancer medicine. The appropriate formulation, dose, treatment schedule, monitoring and duration depend on the patient's diagnosis and clinical circumstances.
Oral azacitidine and injectable azacitidine should not be considered interchangeable. Their approved indications and dosing regimens differ.
Approved indications, dosage recommendations, formulations and regulatory requirements may vary between countries and can change over time. Patients should consult the official product information applicable to their country and follow their treating healthcare professional's instructions.
Do not start, stop, increase or reduce azacitidine treatment without medical advice.
Medical verification: The clinical information above was checked against current FDA prescribing information for oral azacitidine, including the revised April 2026 label.
Need help after reading this?
Talk to our support team for sourcing guidance, product availability, and global delivery assistance.